Express News | D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Benzinga13minutes ago

Anavex Life Sciences Analyst Ratings

Benzinga14minutes ago · Ratings

Express News | Anavex Life Sciences Corp: Blarcamesine Exhibited a Favorable Safety Profile With No Treatment-Related Deaths

Reuters51minutes ago

Express News | Anavex Life Sciences Corp: Topline Attention-Ad Trial: Patients Showed Improved Cognition and Function Over Three Years

Reuters51minutes ago

Express News | New Phase Iib/III Clinical Data Demonstrates Over Three Years of Continuous Treatment With Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

Reuters51minutes ago

Anavex Life Sciences (AVXL) Alzheimer Treatment Sends the Stock to New Heights

TipRanksJan 6 09:50 ET